PRESENTATION BY Professor Michael Butler, Chief Scientific Officer, National Institute of Bioprocessing Research & Training (NIBRT).
PRESENTATION TITLE Control of Mammalian Cell Processes to Ensure Product Quality.
ABSTRACT The clinical application of a biopharmaceutical produced from mammalian cells is dependent upon its structural integrity. One of the critical quality attributes is the glycosylation profile. This can be controlled during upstream processing by cell engineering, media manipulation or by enzymatic re-modelling during downstream processing. The relative value of each of these possible strategies will be evaluated during this presentation.
ABOUT THE PRESENTER Michael Butler is the Chief Scientific Officer at the National Institute of Bioprocessing Research & Training (NIBRT), Ireland, Adjunct Full Professor in University College Dublin as well as Distinguished Professor Emeritus of the University of Manitoba, Canada. He holds degrees in Chemistry and Biochemistry from the Universities of Birmingham, London (UK) and Waterloo (Canada). He was the scientific director of MabNet, a Canadian network for Mab production and founder of Biogro Technologies Inc., a spin-off company dedicated to serum-free media development. His research work focuses on the development of bioprocesses using mammalian cells for the production of recombinant proteins, monoclonal antibodies and viral vaccines.
Tea/coffee will be available at 12h45. For further information, please contact: email@example.com